Apyx Medical

APYX · NASDAQ

$2.44+$0.02 (+0.83%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.42

APYX analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $6.63 (+171.7% upside)

Low: $6.06
Now: $2.44
High: $8.40

Upgrades and downgrades

The latest rating actions, newest first

APYX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Sep 29, 2026	Initiates	Buy	$6.00	—
HC Wainwright & Co.	Jul 13, 2026	Initiates	Buy	$7.00	40%
Craig-Hallum	Mar 11, 2026	Maintains	Buy	$5.00 → $6.00	57%
BTIG	Mar 11, 2026	Upgrade	Neutral → Buy	$6.00	40%
Roth Capital	Dec 16, 2025	Initiates	Buy	$6.00	48%
Citizens	Nov 12, 2025	Upgrade	Market Perform → Market Outperform	$8.00	42%

The case for and against

Updated Aug 26, 2026

Bull case

Apyx Medical is a company with a strong position in the cosmetic surgery market, driven by the success of its Renuvion platform. This platform utilizes a unique helium plasma technology to tighten loose or lax skin. The recently launched Ayon all-in-one body contouring system has the potential to drive further growth by providing a comprehensive solution for surgeons. Apyx's focus on the surgical skin tightening market, favorable market trends, and expanding recurring revenue mix position the company for sustainable cash flow generation and potential valuation multiple expansion.

Bear case

Apyx Medical is expected to experience a decline in revenue due to decreased demand for its Renuvion technology following the FDA's safety communication in 2022, but this could potentially be offset by the launch of its new Ayon product and expanded FDA clearance for its J-Plasma system in 2026. However, risks such as potential liability from product liability matters, inconsistent commercial execution, and regulatory delays could impact the company's financial performance. Additionally, with a history of net losses and significant outstanding debt, the company's financial stability could be a concern.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.